ProCE Banner Activity

MonumenTAL-1: Impact of Dose Modification on Safety and Efficacy of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma

Conference Coverage

Data from the phase I/II MonumenTAL-1 trial show that reducing the frequency or intensity of talquetamab dosing improved tolerability while maintaining responses in patients with relapsed/refractory multiple myeloma.

Released: December 15, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.